Amneal Pharmaceuticals, Inc. 4

Director Jeffrey P. George reported the vesting and conversion of 34,819 restricted stock units into Amneal Pharmaceuticals, Inc. Class A Common Stock and an additional grant of 19,824 RSUs as equity compensation.

On May 7, 2026, reporting person Jeffrey P. George had 34,819 previously granted restricted stock units vest and convert into an equivalent number of Amneal Pharmaceuticals, Inc. Class A Common Stock shares, increasing his directly held common stock to 344,614 shares, while the corresponding RSU balance decreased by the same amount. In addition, a prior RSU grant of 19,824 units dated May 6, 2025 was reported, which also represents a form of equity compensation rather than an open‑market transaction. No explicit transaction prices were provided in the filing, so dollar values must be inferred from market context, but the activity is entirely related to equity awards and vesting rather than discretionary purchases or sales.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032924

Alert Tier

5